A team of researchers from UC Davis, UC San Diego, and other institutions has identified a key mechanism behind aggressive prostate cancer. Published online today in Nature, the study shows that two long noncoding RNAs, PRNCR1 and PCGEM1, activate androgen receptors, circumventing...
Researchers at Moffitt Cancer Center suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF inhibitor therapy with other inhibitors, especially as they become more widely used....
In a study reported in Journal of the National Cancer Institute, Paul Lochhead, MBChB,MRCP, of the Dana-Farber Cancer Institute and Harvard Medical School, and colleagues analyzed the association of microsatellite instability and BRAF status subgroups with survival in patients with colorectal...
Data analyzed from a large cohort study of men diagnosed with prostate cancer found that prostate cancer aggressiveness may be established when the tumor is formed and not change over time. The researchers of the study, Kathryn L. Penney, ScD, Instructor in the Department of Medicine at Harvard...
In a study of ovarian cancer cells taken from patients, scientists from Georgia Institute of Technology have confirmed that metastasizing cancer cells have a different molecular structure from primary tumor cells and display genetic signatures consistent with epithelial-to-mesenchymal transition....
Scientists have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new research in mice suggests that neural stem cells, the body's source of new brain cells, are resistant to radiation, and can be roused from a hibernation-like...
Off-label prescribing of drugs remains common in oncology, but about two-thirds of off-label prescribing is consistent with the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, according to a study reviewed at Best of ASCO Chicago by Monika K. Krzyzanowska, MD, MPH, of ...
Cisplatin plus fluorouracil (5-FU) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and 5-FU in randomized trials in locoregionally advanced head and neck cancers. An updated individual patient data meta-analysis reported in the Journal of Clinical Oncology ...
Parents and siblings of children with cancer have between a two- and four-times increased risk of developing cancer than first-degree relatives with no childhood cancer patients, according to a study published in the International Journal of Cancer. The study, led by Joshua Schiffman, MD, Medical...
In a study reported in Lancet Oncology, Timothy Key, PhD, of Oxford University, and colleagues in the Endogenous Hormones and Breast Cancer Collaborative Group analyzed data from seven prospective studies to determine associations between sex hormones and risk of breast cancer in premenopausal...
The U.S. Food and Drug Administration (FDA) today approved dolutegravir (Tivicay), a new drug to treat HIV-1 infection. Dolutegravir is an oral integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. The drug is taken in combination with other...
According to a study published online today in Cancer Cell, the molecule interleukin-11 may be a potential new target for anticancer therapies. Until now, interleukin-11’s role in cancer development has been underestimated, but researchers have recently identified this molecule as a "dark...
A multistate study led by researchers at the University of Utah has revealed that the risk for childhood cancer is moderately increased among children and young adolescents with certain types of major birth defects. Children born with nonchromosomal birth defects have a two-fold higher risk of...
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. The study, published online in Cancer, indicates that the treatment is a promising alternative for patients whose spinal tumors...
In a study reported in Journal of Clinical Oncology, Kelly-Anne Phillips, MD, of Peter MacCallum Cancer Centre and University of Melbourne, and colleagues analyzed the association of adjuvant tamoxifen use and risk of contralateral breast cancer among women carrying BRCA1 and BRCA2 mutations in the ...
Although small clinical studies of adoptive T-cell therapy in the treatment of advanced forms of leukemia have shown positive results, including putting some patients into complete remissions, progress in the development of this type of immunotherapy is limited by the lack of readily available,...
According to a new study published in the journal Cancer, the survival outcome of patients with Burkitt lymphoma has improved substantially over the past decade, with notable exceptions. To help doctors and researchers better understand who responds well to treatment and who does not, the study...
For the first time, scientists have directly observed events that lead to the formation of a chromosome abnormality that is often found in cancer cells. The abnormality, called a translocation, occurs when part of a chromosome breaks off and becomes attached to another chromosome. The results of...
Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in patients with non–small cell lung cancer that can help predict survival and treatment response. Their findings, published in Carcinogenesis, could help lead to more personalized treatment options and...
Genomic sequencing experts at Johns Hopkins partnered with pharmacologists at Stony Brook University to reveal a striking mutational signature of upper urinary tract cancers caused by aristolochic acid, a plant compound contained in herbal remedies used for thousands of years to treat a variety of...
Minimal data are available on outcomes of second allogeneic hematopoietic stem cell transplantation from unrelated donors after first hematopoietic stem cell transplantation in patients with hematologic relapse of acute leukemia. In a study reported in Journal of Clinical Oncology, Maximilian...
The U.S. Food and Drug Administration (FDA) today approved the first rapid human immunodeficiency virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or fingerstick whole blood specimens. Approved for...
A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence. Knowing that this feature exists in a tumor's pathology could be an important...
Researchers from Indiana University, the University of Michigan, the Fred Hutchinson Cancer Research Center, and the Dana-Farber Cancer Institute have identified and validated a biomarker accessible in blood tests that could be used to predict which stem cell transplant patients are at highest risk ...
A recent study published in the Journal of Oncology Practice assessed the feasibility and value of incorporating patient reported outcomes into oncology practice. Although previous research has shown that using patient-reported outcomes in oncology can improve physician-patient communication and...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Eisai’s investigational compound E7777 for cutaneous T-cell lymphoma. E7777 is designed to have an improved purity profile and manufacturing process. It is currently in a pivotal trial intended to support ...
GlaxoSmithKline announced today that it will discontinue the manufacture and sale of the tositumomab/iodine-131 tositumomab (Bexxar) therapeutic regimen on February 20, 2014. Tositumomab/iodine-131 tositumomab is currently approved in the United States and Canada for the treatment of patients with ...
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have discovered a novel mechanism responsible for the loss of a critical tumor-suppressor gene in rhabdomyosarcoma and other...
In a study reported in Journal of Clinical Oncology, David Margel, MD, PhD, of University of Toronto, and colleagues examined the effect of duration of antidiabetic medication exposure after prostate cancer diagnosis on all-cause and prostate cancer–specific mortality in men with diabetes....
Researchers at Mayo Clinic in Florida have revealed the process by which pancreatitis—chronic inflammation of the pancreas—morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients at risk of pancreatic cancer and to potential drug therapies...
In a phase II study (BREAK-2) reported in Journal of Clinical Oncology, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori Fondazione G. Pascale, and colleagues assessed the activity of the mutated BRAF kinase inhibitor dabrafenib (Tafinlar) in patients with BRAF-V600E/K mutant metastatic...
Patients with advanced chronic lymphocytic leukemia (CLL) often receive allogeneic transplants that effectively “reboot” their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the...
Although celiac disease is associated with an increased risk of lymphoma, including enteropathy-associated T-cell lymphoma, it was not known whether persistent atrophy of the villi, the fingerlike projections that normally absorb nutrients, contributed to that risk. In a large population-based...
Organized mailing campaigns could substantially increase colorectal cancer screening among uninsured patients, according to a study published online in JAMA Internal Medicine. The research also suggested that a noninvasive colorectal screening approach, such as a fecal immunochemical test, might be ...
The results of a large-scale analysis of the association between DNA viruses and human malignancies suggest that many of the most common cancers are not associated with DNA viruses. The findings, published in the August issue of the Journal of Virology, challenge earlier studies suggesting that as...
A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common—and most aggressive—form of brain cancer in adults. The study was published online...
Long-term use of a calcium-channel blocker to treat hypertension is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine. The study assessed the relationships between the major classes of hypertensive agents and risk of the two most common histologic...
Deciphering the body's complex molecular pathways that lead to disease when they malfunction is highly challenging. Researchers at Sanford-Burnham Medical Research Institute now have a more complete picture of one particular pathway that can lead to cancer and diabetes. In a study published in...
Scientists at St. Jude Children’s Research Hospital have discovered a way to target the immune system to shrink or eliminate tumors in mice without causing autoimmune problems. Researchers also found evidence that the same mechanism may operate in humans. The study was published online today...
The contribution of purging of peripheral blood stem cells to outcome of autologous stem cell transplantation in high-risk neuroblastoma has not been defined. In a trial (COG A3973) reported in Lancet Oncology by Susan G. Kreissman, MD, of Duke University Medical Center, and colleagues, children...
Many factors play into why women diagnosed with breast cancer often choose overly aggressive treatment even when there is little evidence to show clinical benefit: the shock and fear of suddenly being confronted with a major health threat, the impression of having to make treatment decisions...
An international research team led by scientists at the University of Pittsburgh Cancer Institute (UPCI) discovered that by preventing cancer cells from entering a state of cellular sleep, cancer drugs are more effective, and there is a lower chance of cancer recurrence. The findings, published...
In the SoFEA trial, reported in Lancet Oncology by Stephen R.D. Johnston, PhD, FRCP, of Royal Marsden NHS Foundation Trust, and colleagues, postmenopausal women with advanced hormone receptor–positive breast cancer that progressed on nonsteroidal aromatase inhibitors were treated with the...
Omega-3 fatty acids, contained in oily fish such as salmon and trout, selectively inhibit growth and induce cell death in early- and late-stage oral and skin squamous cell carcinomas, according to new research from scientists at Queen Mary, University of London. The findings were published online...
The U.S. Food and Drug Administration (FDA) is informing the public that acetaminophen has been associated with a risk of rare but serious skin reactions. These skin reactions, known as Stevens-Johnson Syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis, can...
A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma—a key factor in tailoring patient management plans—has been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine. Imaging with...
In a study reported in The New England Journal of Medicine, María-Victoria Mateos, MD, PhD, of the Universidad de Salamanca, and colleagues compared induction lenalidomide (Revlimid) plus dexamethasone followed by maintenance lenalidomide with observation in patients with high-risk...
Scientists at The University of Texas MD Anderson Cancer Center who identified a protein’s dual role in cancer promotion have discovered a way to shut it down, opening a potential new avenue for cancer treatment. Reporting their findings in the journal Cell, the researchers describe the first ...
Blocking dietary sugar and its activity in tumor cells may reduce cancer risk and progression, according to researchers from the Icahn School of Medicine at Mount Sinai in New York. The study, conducted in fruit flies and published in the August issue of Cell, provides insight as to why...
A new study led by researchers at Sanford-Burnham Medical Research Institute reveals how a promising anticancer compound called SMIP004 specifically kills prostate cancer cells by compromising their ability to withstand environmental stress. The study, recently published in Oncotarget, uncovered...